The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | The effect of futibatinib on hepatic impairment in ICC
Ling Gao, PhD, Taiho Oncology, Inc., Princeton, NJ, discusses findings from a study assessing the effect of futibatinib, an irreversible FGFR1-4 inhibitor, in livers of patients with advanced or metastatic intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 gene fusions. Severity of hepatic impairment was not dependent of exposure to futibatinib, and dose adjustment is, thus, not necessary in patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
